Takeda Pharmaceutical Company Ltd

Six companies—Ionis Pharmaceuticals, Isarna Therapeutics, Regulus Therapeutics, Sarepta Therapeutics, Secarna Pharmaceuticals, and Wave Life Sciences—are leading in the development of antisense oligonucleotides, a targeted treatment for various diseases. Ionis, a pioneer with over 40 drugs in its pipeline, recently priced a $500 million IPO. Isarna's ISTH0036 targets TGF-β for ophthalmic conditions. Regulus focuses on microRNA targeting with its lead candidate RGLS8429 for ADPKD. Sarepta has three approved PPMO therapies for DMD and a recent $1 billion deal with Arrowhead Pharmaceuticals. Secarna's SECN-15 targets NRP1 for oncology. Wave Life Sciences' WVE-003, for Huntington's disease, recently reported positive phase 1b/2a trial results. The antisense oligonucleotide market is projected to grow to $5,519 million by 2033.

Ascentage Pharma's olverembatinib, a third-generation BCR-ABL inhibitor, has its new indication for adult patients with chronic-phase chronic myeloid leukemia (CML-CP) resistant and/or intolerant of first-and second-generation tyrosine kinase inhibitors (TKIs) included in the China 2024 National Reimbursement Drug List (NRDL), effective January 1, 2025.

Global Human Growth Hormones Market to reach USD 10 billion by 2030, driven by increasing prevalence of growth hormone deficiency, product approvals, and adoption of recombinant HGH. North America dominates the market, with key players including Novo Nordisk, Pfizer, and Eli Lilly. Market growth is fueled by advancements in biotechnology and rising demand for targeted therapies, despite challenges like stringent regulations and high treatment costs.

Vivo, developed by OmniScience, won the CNS Summit Innovation Showcase for its ability to streamline clinical trial data accessibility and support actionable insights. The platform's genAI capabilities enable teams to make informed decisions, reducing trial timelines and increasing success rates.

The National Reimbursement Drug List (NRDL) faces budget pressure and competition, with 445 drugs passing formal review in 2024. Oncology, immunology, neurology, and rare diseases see strategic positioning and comparator choices as key. Contract renewals and re-negotiations are under pressure, emphasizing clear messaging and data preparation for NRDL success.

Neuroendocrine Tumors Market to grow at 5.1% CAGR (2020-2034) driven by upcoming therapies, rising incident cases, and increased research. Key players include Novartis, ITM Solucin GMBH, Camurus, Bristol Myers Squibb, Rayzebio, Exelixis, Ipsen, Takeda. DelveInsight's report covers current treatment practices, emerging drugs, market share, and forecasted market size in 6MM.

AffyImmune Therapeutics appoints Deyaa Adib, M.D., as Chief Medical Officer, bringing 28 years of oncology experience. Adib will oversee clinical activities, including strategic direction and execution of development programs. He has led successful registrations in solid tumor and hematologic malignancy indications and has held CMO roles at FibroGen, Triumvira Immunologics, Rain Therapeutics, and Blueprint Medicines.

GSK’s Blenrep, withdrawn in 2022, seeks FDA approval in combination with Velcade/dexamethasone or Pomalyst/dexamethasone for multiple myeloma patients with prior therapy. Based on DREAMM-7 and DREAMM-8 trials, Blenrep combos showed significant PFS improvements over standard-of-care, with manageable safety profiles. Expected to compete with BCMA CAR-T therapies like Carvykti and Tecvayli, Blenrep could offer simpler IV infusion benefits.

Asia-Pacific leads in vaccine development with 46% of global prophylactic trials and 31% of therapeutic trials, driven by technological innovations, strategic investments, and regional collaborations. The industry shifts from prophylactic to therapeutic applications, with mRNA and viral vector platforms, genomics, AI, and therapeutic innovations in oncology shaping the future. Challenges include vaccine equity, regulatory complexities, and public hesitancy, but strategic investments and collaborations are reshaping the sector.